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Previous studies have suggested alterations in pulmonary surfactant lipid in the setting of Pneumocystis carinii
pneumonia in HIV-infected patients. Because pulmonary surfactant lipid is composed of a variety of lipid products
and because other phospholipids might be present in bronchoalveolar lavage (BAL) lipid determinations, a single
molecular species of phospholipid which comprises a substantial portion of the surfactant lipid fraction, dipalmitoyl
phosphatidylcholine (DPPC), was measured by capillary column gas chromatography in BAL samples taken at the
time of the diagnosis of P. carinii pneumonia, and 10 days after treatment for P. carinii pneumonia. DPPC was
measured at day 0 and day 10 in seven patients who had been randomized to receive methylprednisolone adjuvant
therapy for P. carinii pneumonia and in six patients who had been randomized to not receive methylprednisolone
therapy. The level of DPPC in BAL from all patients at day 0 was 0·49&0·06 ìg ml"1 BAL. This level is
significantly lower that the level of DPPC determined in BAL from five normal volunteers 2·48&0·40 ìg ml"1. At
day 0, the BAL level of DPPC in patients treated with methylprednisolone was not diVerent from the BAL level of
DPPC in patients not treated with methylprednisolone. By day 10 of therapy for P. carinii pneumonia, BAL levels
of DPPC in all patients had increased to 1·05&0·19 ìg ml"1 BAL. At day 10 DPPC levels in the methyl-
prednisolone treated group were not diVerent from the group not treated with methylprednisolone. We conclude
that in HIV-infected patients, lung surfactant lipid is reduced in the setting of P. carinii pneumonia. The lipid levels
return toward normal levels with treatment. Adjuvant therapy with corticosteroids does not alter the rate of recovery
of surfactant lipid levels at least after 10 days of therapy.
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Pneumocystis carinii pneumonia (PCP) is still a common
lung disease aVecting patients with HIV infection. It can
cause a life-threatening pneumonia if therapy is not
instituted promptly. The mechanism by which Pneumo-
cystis causes lung damage and abnormal gas exchange,
however, is not well understood. Possible mechanisms
might include alveolar filling, damage to the type I or type
II cells in the alveolar space as a direct eVect of the0954-6111/99/060373+06 $12.00/0organisms or as an eVect of activation of macrophages,
lymphocytes or fibroblasts as a part of the inflammatory
response to the organism. If the pneumonic process
results in damage to alveolar type II cells, production of
pulmonary surfactant may be altered.
Human pulmonary surfactant is a complex mixture of
glycerolphospholipids, other lipids, and surfactant proteins.
The composition of the glycerolphospholipids includes
primarily dipalmitoyl-phosphadidylcholine (DPPC), other
species of phosphatidylcholine, and phosphatidylglycerol
(1). Studies investigating the eVect of HIV infection and
P. carinii pneumonia on the lipid and protein component
of pulmonary surfactant have suggested abnormalities
(2–4). When the total lipid quantity from bronchoalveolar
lavage fluid was analysed, variable results were reported
(2,3,5). One study reported a reduction in BAL total? 1999 W. B. SAUNDERS COMPANY LTD
374 J. R. DICHTER ET AL.phospholipids and phosphatidylcholine separated by thin
layer chromatography and assayed as organic phosphorus.
In a separate study, normal volunteers and HIV-infected
patients without PCP had significantly higher levels of
BAL phospholipid assayed by gas chromatography than
patients with a mild episode of PCP or moderate to severe
PCP (3). There was a parallel fall in diacylglycerol lipids,
suggesting that native surfactant lipid was not merely
degraded, but that production was reduced (3). A separate
study which utlilized enzymatic assays of phospholipids did
not find a decrease in BAL phosphatidylcholine or phos-
pholipid and found an increase in phosphatidylglycerol
in BAL fluid of HIV-infected patients with P. carinii
pneumonia (5). Experimental animal models of P. carinii
pneumonia also suggest abnormalities of lung surfactant
(6,7). Rats treated with dexamethasone who then develop
P. carinii pneumonia have reduced levels of lung lavage
phosphatidylcholine and other phospholipids, while ani-
mals treated with dexamethasone who do not develop P.
carinii pneumonia have higher levels than untreated rats
(6). The increase in lung lavage phosphatidylcholine in
dexamethasone-treated rats is consistent with the pre-
viously reported increase in phosphatidylcholine produc-
tion by fetal pneumocytes treated with dexamethasone (1).
Moreover, the adverse eVect of P. carinii pneumonia on
surfactant lipid production by pneumocytes is suggested by
in vitro studies of type II pneumocyte function. Isolated
alveolar type II cells from rats with P. carinii pneumonia
incorporate less radiolabelled choline into secreted phos-
phatidylcholine than do type II cells from rats without
P. carinii pneumonia (7).
It is postulated that the inflammatory or immune
response to the organism is in part responsible for severe
abnormalities of gas exchange noted in the setting of
P. carinii pneumonia. This theory led to the study of
adjunctive glucocorticosteroid therapy to prevent or
ameliorate this eVect (8–11). Though these studies
provided evidence of eYcacy in terms of decreased
hypoxaemia and mortality, and lead to the consensus
statement regarding steroid use in PCP (12), the mechan-
ism of this eVect is not well understood. As was pre-
viously noted, glucocorticosteroid treatment of alveolar
type II cells may increase cellular production of surfactant
phosphatidylcholine (1). If a decrease in the level of
surfactant lipid is a sequela of human P. carinii pneu-
monia, then it seems possible that glucocorticosteroid
therapy might preserve lung function by minimizing this
loss.
It was the purpose of this project to investigate whether a
major molecular species of surfactant lipid, DPPC, is
reduced in the setting of P. carinii pneumonia and to study
whether adjuctive glucocorticosteroid therapy in the setting
of P. carinii pneumonia increases the quantity of lung
surfactant lipid. In order to answer this question, surfactant
lipid was extracted and quantitated from bronchoalveolar
lavage fluid obtained from HIV-infected patients with P.
carinii pneumonia who were part of a randomized
study measuring the eVect of standard therapy plus
either methylprednisolone (2 mg kg"1 day"1) or no
methylprednisolone treatment (8).Methods
As part of a large, multicentre study, patients were
randomized to receive either methylprednisolone
(2 mg kg"1 day"1) or no adjunctive therapy, as described
previously (8). Therapy for P. carinii pneumonia was
started after the first bronchoscopy and bronchoalveolar
lavage (BAL). The total volume instilled was that required
to obtain a return of approximately 100 ml. The average
volume instilled on day 0 was 220&10 ml and on day 10
was 226&13 ml. Average return was 55&4% (n=13) on
day 0 and 51&4% (n=11) on day 10. The fluid was
transported to the laboratory on ice, centrifuged at
1500#g for 10 min to remove cells and P. carinii organisms
and aliquots of supernatant were then frozen at "20)C
until studied. BAL from five normal volunteers was pro-
cessed in the same manner. Aliquots of BAL (0·50–1·0 ml)
were centrifuged for 1 h at 82 000#g to pellet the sur-
factant lipid. The lipid pellet was then quantitatively trans-
ferred using three aliquots of 1·0 ml of 0·9% saline, and
added to 10 ìg of C15, C15-PC dried previously under N2.
This solution was then lyophilized. C15, C15-PC is a
non-physiological lipid which was used as an internal yield
standard for the extraction procedure. The lyophilized
material was then extracted using a modified Folch pro-
cedure (13) in which the lyophilized lipids were first placed
in 10 ml of cold chloroform:methanol (2:1), and then 2·5 ml
of distilled H2O were added. The lipid layer was then
removed from under the aqueous layer, percolated through
Na2SO4, dried under N2, and resuspended in 50 ìl of C/M
2:1.
The lipids were then separated by two dimensional thin
layer chromatography (TLC) by the method of Rouser (14)
using silica H plates with 7·5% magnesium acetate
(Analtech Corp., Newark, Delaware, U.S.A.). The lipids
were visualized by spraying with fluoroscein, exposing to
fumes from 30% NH4OH, and then visualizing under
ultraviolet light. The PC spots were then removed from the
plates, and the lipids re-extracted from the TLC silica using
the method of Arvidson (15).
The choline moiety was hydrolysed from the PC to
form the equivalent 1,2-diacylglycerol compounds using
10 U of phospholipase C, type I, from C. perfringens (3)
(Sigma Corporation, St. Louis, MO, U.S.A.) and shaken
for 1 h at 40)C. The hydrolysed lipids were extracted by
adding 10 ml of C/M 2:1, and the lower, organic layer
removed and percolated through sodium sulphate. Two
micrograms of Tridecanoin (TDC), the internal standard,
were added at this point, and the lipid mixture dried under
nitrogen.
The trimethylsilyl derivatives of the lipids were then
formed by adding 100 ìl Trisyl-BSA, formula P (Pierce
Chemicals, Rockford, IL, U.S.A.) and incubating for 1 h at
40)C. The lipids were dried under N2 and suspended
in 100 ìl hexane, in preparation for analysis by gas
chromatography.
For gas chromatographical analysis, the lipid samples
(2 ìl each) were injected into a Hewlett-Packard 5880 gas
chromatograph (Hewlett-Packard Corporation, Kennett
Square, PA, U.S.A.) equiped with an automatic liquid
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employed was a 15-m, 0·25-mm, aluminum-clad capillary
column coated with 5% phenyl silicone (Quadrex
Corporation, New Haven, CT, U.S.A.), attached to a
2-m, 0·53 mm, uncoated, deactivated guard column
(Hewlett-Packard Corporation). The temperature program
was as follows:
1. Initial temperature 50)C for 5 min, followed by:
2. 30) min"1 to 150), final time at 150)=0 min;
3. 20) min"1 to 230), final time at 230)=0 min;
4. 10) min"1 to 280), final time at 280)=0 min;
5. 5) min"1 to 340), final time at 340)=30·37 min.
The quantities of both the C15,C15-PC and C16,C16-PC
were calculated by comparison to known standards (16).
All samples were run blinded.
Statistical analysis of BAL lipid levels in the two
groups was done by unpaired t-test in Microsoft Excel.
Comparison of the changes in BAL lipid levels from day 0
to day 10 was done by paired-sample two-tailed t-test.












Sex 11 men 6 men 5 men
2 women 1 woman 1 woman
Age (years) 44&3·1 48&4·5 38·8&3·4
PaO2 (mmHg) 55&2·9 59·5&2·7 50&5·1
A–a diVerence (mmHg) 50·7&3·6 50&4·5 51·8&6
CD4 count (cells mm"3) 44&16 27·0&10 63·5&33·5



























Fig. 1. Representative chromatogram of BAL DPPC of a patient with P. carinii pneumonia at day 0 (a) and day 10 (b).
See Methods section for details. TDC, tridecanoin; C-15 PC, C-15, C-15 phosphatidylcholine; C-16 PC, dipalmitoylphos-
phatidylcholine (DPPC).Results
Surfactant lipid from matched day 0 and day 10 BAL
specimens was extracted from 13 patients (26 specimens in
total). The clinical characteristics from these 13 patients are
shown in Table 1. Overall, of the 13 patients who had BAL
procedures, 11 were men and 2 were women. Seven patients
(6 men, one woman) were randomized to recieve methyl-
prednisolone and six patients (five men, one woman) were
randomized to receive no methylprednisolone therapy.
There were no significant diVerences between the two
groups in terms of age, room air PaO2 on admission,
alveolar–arterial (A–a) O2 diVerence, CD4 count, or serum
lactate dehydrogenase (LDH) level on admission.
Representative chromatographs of BAL from a patient
with P. carinii pneumonia who had BAL performed at day
0 (left panel) and day 10 (right panel) are presented in Fig.
1. The overall yield for the BAL lipid extraction procedure,
as measured by C15,C15-PC recovery was 40%.
The levels of dipalmitoyl phosphatidyl choline (DPPC) in
BAL expressed in ìg DPPC ml BAL"1 are shown in Table
376 J. R. DICHTER ET AL.2. For all patients, at the time of diagnosis of P. carinii
pneumonia, the measured level of DPPC was 0·49&
0·06 ìg ml BAL"1. For patients who did not receive
methylprednisolone therapy, the level of DPPC at day 0
was 0·45&0·11 ìg ml BAL fluid"1. This level was not
diVerent from the DPPC level measured at day 0 in patients
randomized to receive methylprednisolone adjunctive
therapy (0·53&0·06 ìg ml BAL"1). By day 10 the average
DPPC level had increased to 1·05&0·19 ìg ml BAL"1 in
the group as a whole (P0·02 vs. day 0). At day 10, the DPPC
level for those who had received methylprednisolone
therapy was not diVerent from those who had not
(1·03&0·29 vs. 1·07&0·24 ìg ml BAL"1, respectively)
(Table 2). At both time-points, BAL DPPC levels were
significantly decreased when compared to surfactant lipid
extracted from BAL fluid from five normal volunteers
(2·48&0·40 ìg ml BAL fluid"1, P<0·05). The changes in
BAL DPPC in paired samples between day 0 and day 10 of
treatment are presented in Table 3. Within the two groups,
the increase in DPPC level from day 0 to day 10 did not
reach statistical significance in the methylprednisolone
treated patients and was significantly higher in the patients
not receiving methylprednisolone therapy (P=0·02). There-
fore, levels of DPPC in BAL of patients with P. carinii
pneumonia are low at the time of diagnosis of pneumonia
and return towards normal with treatment of the
pneumonia.Table 2. Surfactant lipid levels comparison between methylprednisolone and placebo-treated
patients: days 0 to 10
Day All patients Patients receiving methylprednisolone Patients receiving placebo P-value†
0 0·49&0·06* 0·53&0·06 0·45&0·11 n.s.
10 1·05&0·19 1·03&0·29 1·07&0·24 n.s.
*ìg DPPC ml BAL"1&sem.
†Comparing diVerent patient groups at day 0 or day 10 (n.s., not significant).Table 3. Surfactant lipid levels changes between day 0 and day 10
Change days 0–10
(ìg DPPC ml BAL"1&sem) P-value
Patients receiving methylprednisolone 0·50&0·31 0·16
Patients receiving no adjunctive therapy 0·61&0·2 0·02
Results are in ìg of C16, C16-PC ml BAL"1.Discussion
Despite the advent of eVective regimens of prophylaxis, P.
carinii pneumonia is still a cause of morbitity in HIV-
infected patients (17,18). The specific mechanisms by which
P. carinii pneumonia causes hypoxaemia are not well under-
stood (19). Interstitial inflammation, alveolar exudate and
possibly surfactant depletion might all play a significantrole. Alterations of pulmonary surfactant lipid, surfactant
protein concentration and surfactant activity have been
reported in a variety of types of lung injury. In humans,
acute lung injury is associated with decreases in BAL phos-
phatidylcholine and surfactant protein A (20,21). In adults
with bacterial pneumonia and in children with bacterial or
viral pneumonia, surfactant protein A concentrations may
be reduced (22,23). The proinflammatory cytokine tumour
necrosis factor (TNF) inhibits the production of surfactant
protein A by isolated alveolar type II cells (24,25). In
experimental animal models of acute lung injury, alterations
in disaturated phosphatidylcholine have been reported in
lung injury induced in dogs (26) and in rabbits (27). Simi-
larly, changes in lung lavage phosphatidylcholine have been
reported in a rat model of P. carinii pneumonia (6).
We utilized a measurement of a single molecular species
of phospholipid (DPPC) which is characteristic of pulmon-
ary surfactant in order to assess more specifically any
changes in surfactant lipid in the BAL of patients with P.
carinii pneumonia. At the time of diagnosis of P. carinii
pneumonia, surfactant DPPC was significantly reduced in
all. By day 10 of treatment for P. carinii pneumonia, BAL
DPPC was significantly higher than at day 0; although,
BAL DPPC at day 10 was still lower than that measured in
normal volunteers. The measured levels of DPPC from
BAL were lower than might have been expected if previous
studies of BAL diacylglycerol lipids reflect only surfactant
lipid. This diVerence may be accounted for by losses in
additional separation precedures necessary to measure only
DPPC or perhaps by the presence of other non-surfactant
diacylglycerol lipids in BAL.
While a reduction in BAL phospholipid or phosphatidyl-
choline in HIV infected patients with P. carinii pneumonia
has been previously reported (2,3), others have reported no
reduction in total BAL phospholipid or phosphatidyl-
choline (5). The diVerences in these reports may relate to
diVerent assay methods or to diVerences in processing
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bind surfactant protein A (19). It seems possible that
the organism binds to surfactant protein and lipid and
that removal of the organism removes surfactant lipid
as well.
Corticosteroid adjunctive therapy in patients with P.
carinii pneumonia appears to modulate the activity of
macrophages and lymphocytes participating in the inflam-
matory response in the lung and thereby prevent a substan-
tial decline in gas exchange during initial therapy (28,29).
Given the experimental evidence that corticosteroid therapy
is capable of stimulating alveolar type II cell production of
phosphatidylcholine, it seemed possible that adjuvant cor-
ticosteroid therapy might induce an increase in BAL levels
of DPPC. At least at day 10, there was no evidence that
adjunctive therapy with glucocorticosteroids made a diVer-
ence in the level of lung surfactant as measured by BAL
DPPC.
The importance of these observations may not be
known until the ability to modulate surfactant levels and
surfactant activity in the alveolar space is more clearly
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